Tempest Therapeutics (TPST) AI Stock Analysis

Tempest Therapeutics is currently unprofitable, as reflected in its negative EPS and PE ratio. The magnitude of the loss per share suggests the company is still in a cash-consuming, development-heavy phase rather than a revenue-generating one. Without evidence of improving earnings trends or a path to profitability, the financial profile is high risk and fundamentally weak for equity holders.

• Negative EPS of -5.70 indicates substantial net losses, typical of early-stage biotech but still materially dilutive to shareholder value over time.
• A PE ratio of -0.22 confirms there are no positive earnings to support the current valuation, so the stock trades purely on expectations of future clinical and regulatory success.
• Absent signs of improving profitability or revenue growth, the financial picture suggests continued dependence on external financing (equity or debt), which can pressure the stock further.

The stock trades at $1.27, down 39.2% over the last month, signaling strong negative momentum. With the price far below its 200-day moving average of $4.79, the technical setup points to a pronounced downtrend and damaged sentiment. Unless there is a clear catalyst, the current pattern suggests continued volatility and downside risk rather than a confirmed recovery.

• A 39.2% decline in one month reflects aggressive selling pressure and likely capitulation by shorter-term holders.
• The current price ($1.27) is dramatically below the 200-day moving average ($4.79), a classic sign of a sustained downtrend and technical weakness.
• While an oversold RSI could eventually emerge as a short-term trading opportunity, the broader technical picture is dominated by negative momentum and broken longer-term support levels.

Overall, Tempest Therapeutics appears fundamentally and technically weak at this time. Persistent losses, a sharp recent price decline, and a stock trading well below its long-term moving average point to elevated risk and fragile sentiment. With alternative data showing only modest, flat activity, the current setup skews bearish until there is clear evidence of clinical, financial, or strategic catalysts that can reverse the trend.

• Negative earnings and lack of profitability, combined with reliance on future expectations, make the equity highly speculative.
• Severe underperformance versus the 200-day moving average and a near-40% monthly drop in price underscore a bearish technical environment with significant downside and volatility risk.